Connect with us


Third member of US FDA advisory panel resigns over Alzheimer’s drug approval – Fox Business



Article feature image

A third member of a panel of outside advisers to the U.S. Food and Drug Administration has resigned in protest over the agency’s decision to approve Biogen Inc’s Alzheimer’s disease treatment despite the committee’s recommendation against doing so.

Click here to view the original article.

Continue Reading

You might also like ...

Article feature image
This hedge fund invested in GameStop — it’s now closing after suffering losses: reports – MarketWatch
Article feature image
Amazon’s Planned Purchase of MGM Faces FTC Scrutiny – The Wall Street Journal
Article feature image
EU antitrust regulators launch probe into Google’s FLoC plan – Ars Technica